Rajesh Rao je proslijedio/a tweet korisnika/ceOphthalmology
Authors @UvA_Amsterdam @VUamsterdam @LUMC_Leiden @univgroningen @VUmcAmsterdam
@QUBelfast @Radboud_Uni @radboudumc @UMCUtrecht @erasmusuni @unil note: "In our study, patients were treated monthly for 6 months, which is more frequent than most common regimens in daily practice."https://twitter.com/AAOjournal/status/1222610842056904704 …
Rajesh Rao je dodan/na,
Ophthalmology @AAOjournal
Based on change in visual acuity, bevacizumab (n=138) is non-inferior to ranibizumab (n=138) for patients with macular edema due to retinal vein occlusion of either subtype, when receiving monthly injections for a period of 6 months http://ow.ly/fyGn50xX1f8 pic.twitter.com/anHaAsnfHS
13:51 - 31. sij 2020.
0 replies
3 proslijeđena tweeta
3 korisnika označavaju da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.
| Surgeon•Scientist